<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243074/" ref="ordinalpos=4077&amp;ncbi_uid=4483141&amp;link_uid=PMC3243074" image-link="/pmc/articles/PMC3243074/figure/F3/" class="imagepopup">Figure 3. Therapies modulating the autophagy lysosomal <span class="highlight" style="background-color:">pathway</span>.  From: AUTOPHAGY IN BRAIN TUMORS: A NEW TARGET FOR THERAPEUTIC INTERVENTION. </a></div><br /><div class="p4l_captionBody">Tyrosine kinase inhibitors (monoclonal antibodies and small molecules) block RTK/Ras signaling upstream of the PI3K-Akt-mTOR axis. Inhibitors for PI3K and/or mTOR act on their specific targets resulting in the inhibition of mTOR which induces autophagy. BH3 mimetics induce autophagy by disrupting the Beclin-Bcl-2 interaction. These agents when combined with lysosomotropic drugs result in the disruption of the autophagy-lysosomal pathway, leading to accumulation of autophagic vacuoles ultimately resulting in tumor cell death.</div></div>